Apr 17, 2018
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress(TM) 2018
Apr 17, 2018
Laboratory for Advanced Medicine Presents Findings on Blood-Based Test for Liver Cancer Detection and Prognosis at 2018 AACR Annual Meeting
Apr 09, 2018
Blue Faery Grants Liver Cancer Research Award to Dr. Ghassan Abou-Alfa
Mar 21, 2018
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
Mar 08, 2018
Donor Determined to Shine Light on Cancers of the Hepatobiliary System Gives Second Donation of $10K to The Bili Project Foundation
Mar 05, 2018
Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress(TM) Meeting
Mar 01, 2018
Medivir: New Preclinical Data on MIV-818 Accepted for Presentation at EASL's HCC Summit in March
Jan 08, 2018
Ascentage Pharma Announces Acceptance of IND Application by China FDA for Clinical Study of Novel IAP Inhibitor to Treat Hepatitis B Infection
Jan 08, 2018
Successful Completion of Pre-clinical Safety Studies With MIV-818, Enabling Start of Phase I Clinical Studies in 2018
Dec 12, 2017
BTG plc: Northwestern University Adopts Y90 TARE with TheraSphere® as First-Line Treatment for HCC
Nov 16, 2017
Dr. Eric Lawitz, of the Texas Liver Institute, Publishes on a New Standard of Care for Patients With Chronic Hepatitis C Infection and Severe Renal Impairment
Nov 08, 2017
New Multidisciplinary Liver Tumor Program Targets Liver Cancer
Oct 18, 2017
NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research
Oct 16, 2017
Mars and Partners Launch Uncommon Collaboration to Crowdsource Gaming Solutions that Solve Aflatoxin
Oct 12, 2017
Merck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection
Oct 09, 2017
First Patient Treated With Microscopic Beads Pre-loaded With a Targeted Cancer Drug and Visible on CT Scans
Sep 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
Aug 21, 2017
Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference
Aug 10, 2017
Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
Jul 21, 2017
SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer